---
title: A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood
nct_id: NCT07081932
overall_status: COMPLETED
phase: PHASE1
sponsor: Boehringer Ingelheim
study_type: INTERVENTIONAL
primary_condition: Healthy
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07081932.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07081932"
ct_last_update_post_date: 2025-10-14
last_seen_at: "2026-05-12T07:25:06.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood

**Official Title:** The Effect of Multiple Oral Doses of Bosentan on the Single Oral Dose Pharmacokinetics of Nerandomilast in Healthy Male Subjects (an Open-label, Two-treatment, Two-period Fixed Sequence Trial)

**NCT ID:** [NCT07081932](https://clinicaltrials.gov/study/NCT07081932)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 16
- **Lead Sponsor:** Boehringer Ingelheim
- **Conditions:** Healthy
- **Start Date:** 2025-08-26
- **Completion Date:** 2025-10-08
- **CT.gov Last Update:** 2025-10-14

## Brief Summary

The main objective of this trial is to investigate the effect of bosentan, a moderate Cytochrome P450 (CYP) 3A inducer on the single dose pharmacokinetics of nerandomilast.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 55 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria :

1. Healthy male trial participant according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), bodyweight, 12-lead electrocardiogram (ECG), and clinical laboratory tests
2. Age of 18 to 55 years (inclusive)
3. Body Mass Index (BMI) of 18.5 to 29.9 kg/ m² (inclusive)
4. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial

Exclusion Criteria :

1. Any finding in the medical examination (including Blood pressure (BP), Pulse rate (PR) or electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant by the investigator
2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders assessed as clinically relevant by the investigator
6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders including but not limited to depression and suicidal behaviour
8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
```

## Arms

- **Nerandomilast alone followed by nerandomilast + bosentan** (EXPERIMENTAL)

## Interventions

- **Nerandomilast** (DRUG) — Nerandomilast
- **Bosentan** (DRUG) — Bosentan

## Primary Outcomes

- **Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)** _(time frame: Up to 4 days)_
- **Maximum measured concentration of the analyte in plasma (Cmax)** _(time frame: Up to 4 days)_

## Secondary Outcomes

- **Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)** _(time frame: Up to 4 days)_

## Locations (1)

- Humanpharmakologisches Zentrum Biberach, Biberach, Germany

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.humanpharmakologisches zentrum biberach|biberach||germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07081932.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07081932*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*